Printer Friendly

Suspended THA trials are on again.

Suspended THA trials are on again

Enthusiasm over the potential of tetrahydroaminoacridine (THA) as a treatment for Alzheimer's disease waned last fall, amid questions about the original research and the suspension of a large clinical trial because of serious side effects (SN: 11/7/87, p.292). But now that study is being resurrected, with federal approval. Warner-Lambert Co. of Morris Plains, N.J. -- which manufactures the drug for other purposes -- had started its own clinical trial last year after scientists began questioning earlier research suggesting THA slows memory loss in Alzheimer's patients. But after eight patients in the Warner-Lambert study developed high levels of liver enzymes, the company discontinued the trial, which at the time included about 50 patients. Now the Food and Drug Administration says that, because the patients' enzyme levels returned to normal after drug use stopped, it will allow resumption of the THA trials under different guidelines and at reduced doses.
COPYRIGHT 1988 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1988, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:use of tertahydroaminoacridine for Alzheimer's disease
Publication:Science News
Date:Apr 30, 1988
Previous Article:Report raises blood pressure awareness.
Next Article:Tree planting: the 'greenhouse' effects.

Related Articles
Early trials of Alzheimer drug positive.
THA trials suspended, research probed.
Probe turns up flaws in Alzheimer's study.
Alzheimer's drug fails panel review.
Alzheimer's: slowing the decline.
Alzheimer drug will get wider testing.
Mossy memory-booster for Alzheimer's?
Alzheimer's disease vaccine abandoned. (Biomedicine).
New drug available next month for moderate to severe Alzheimer's disease.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters